Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 6, Issue 3, 2004, Pages 154-161

  Bonomi, Philip D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Paclitaxel poliglumex; Pemetrexed; Taxanes; Tyrosine kinase

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CELECOXIB; CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FOLIC ACID; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; NAVELBINE; PACLITAXEL; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PEMETREXED; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATIENT SELECTION; PROGNOSIS; PRURITUS; REVIEW; SALVAGE THERAPY; SKIN MANIFESTATION; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 10244223949     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.028     Document Type: Review

References (52)

1. American Cancer Society. Cancer Facts and Figures 2004. Atlanta: ACS, 2004.
2. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 2: advanced disease. Oncology 2003; 17:457-484.
3. Le Chevalier T. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell cancer. Semin Oncol 2003; 30(suppl 10):37-44.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:889-890.
5. Bonomi P, Kim KM, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623-631.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
7. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group. J Clin Oncol 2003; 21:3016-3024.
8. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
9. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non - small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291.
10. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:384-388.
11. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388-394.
12. Gatzemeier U, Neuhauss R, Schluter I, et al. Single-agent paclitaxel as a 3-hour infusion. Semin Oncol 1996; 23(suppl 16):94-97.
13. Alberola V, Resell R, Gonzalez-Larriba JL, et al. Single-agent taxol, 3-hour infusion, in untreated non-small-cell lung cancer. Ann Oncol 1995; 6(suppl 3):S49-S52.
14. Ranson MR, Jayson G, Perkins S, et al. Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. Semin Oncol 1997; 24(suppl 12):S12-6-S12-9.
15. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996; 14:142-148.
16. Furuse K, Naka N, Takada M, et al. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology 1997; 54:298-303.
17. Tester WJ, Jin PY, Reardon DH, et al. Phase II study of patients with metastatic non-small cell lung carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 1997; 79:724-729.
18. Sekine I, Nishiwaki Y, Watanabe K, et al. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 1996; 2:941-945.
19. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995; 13:1609-1614.
20. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:1074-1080.
21. Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999; 4:408-416.
22. Huisman C, Smit EF, Giaccone G, et al. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000; 18:3722-3730.
23. Hanna N, Paul S, De Marinis F, et al. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41(suppl 2):24-28 (Abstract #O-5).
24. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer 2003; 39:55-61.
25. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
26. Fossella FV, DeVore R, Kerr RN, et al, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18:2354-2362.
27. Gridelli C, Illiano A, Salvagni S. et al. Effect on quality of life (QOL) of weekly versus 3-weekly docetaxel (D) in second-line treatment of advanced non-small cell lung cancer. The DISTAL randomized phase III study. Proc Am Soc Clin Oncol 2003; 22:625.
28. Schuette W, Nagel S, Serke M, et. al. Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with versus three-weekly docetaxel. Results of randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23:622.
29. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29(suppl 18):3-17.
30. Vogelzang NJ, Rusthoven J, Symanowski J, et al. Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644.
31. Vogelzang NJ, Emri S, Boyer MJ, et al. Effect of folic acid and vitamin b12 supplementation on risk-benefit ratio from phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22:657 (Abstract #2644 ).
32. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002; 13:737-741.
33. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17:1194-1199.
34. Smit EF, Mattson K, Von Pawel J, et al. ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003; 14:455-460.
35. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.
36. Li C, Newman RA, Wallace S. Reformulating paclitaxel. Sci Med 1999;6:38-47.
37. Singer JW, Baker B, De Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate. In: Polymer Drugs in the Clinical Stage. New York: Kluwer Academic/Plenum Publishers, 2003:81-99.
38. Singer JW, Baker B, de Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAXTM], a biodegradable polymeric drug conjugate. Adv Exp Med Biol 2003; 519:81-99.
39. Shipley D, Greco A, Jones S, et al. Phase I study of CT-2103 in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:704 (Abstract #2833).
40. Nemunaitis J, Bolton MG. Phase I study of CT-2103/carboplatin in patients with solid rumors. Eur J Cancer 2003; 1(suppl 5):S171 (Abstract #566).
41. Bodkin, D, Neubauer M, Harper H, et al. Phase 2 study of first-line chemotherapy using CT-2103 in patients with non-small cell lung cancer who are >70 years of age or performance status (PS)=2. Eur J Cancer 2003; 1(suppl 5):S242 (Abstract #806).
42. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
43. Kris M, Natale R, Herbst R, et al. Efficacy of gefitinib, an inhibitor of the epidermail growth factor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial (IDEAL 2). JAMA 2003; 290:2149-2158.
44. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:1-11.
45. Ochs J, Grous JJ, Warner KL. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP). Proc Am Soc Clin Oncol 2004; 23:628 (Abstract #7060).
46. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:1103-1109.
47. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of response nd survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22:3238-3247.
48. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st tine or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 2004; (Abstract #7002).
49. Csiki I, Williams MK, Shyr Y, et al. Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:837 (Abstract #9527).
50. Nugent FW, Graziano S, Levitan N, et al. Docetaxel and COX-2 inhibition with celecoxib in relapsed/refractory non-small cell lung cancer (NSCLC): promising progression-free survival in a phase II study. Proc Am Soc Clin Oncol 2003; 22:671 (Abstract #2697).
51. Johnson DH, Csiki I, Gonzalez A, et al. Cyclooxygenase-2 (COX-2) inhibition in non-small cell lung cancer (NSCLC): preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003; 22:640 (Abstract #2575).
52. Chaplen RA, Kalemkerian GP, Wozniak A, et al. Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 23:638 (Abstract #7102).